Find us at booth # 610

Looking for a way to improve the limit of detection for low-frequency mutations, gene fusions, and CNVs?

Explore NuProbe’s research technologies for oncology biomarker detection and monitoring at the 2023 AACR Annual Meeting, in Orlando, FL. Visit our booth to learn more about our technologies for heme malignancy and solid tumor applications.

Applications of Blocker Displacement Amplification in Oncology Research

Exhibitor Spotlight Theater Presentation (Session ESP08D)
Spotlight Theater D | April 18, 2023, at 3:00 PM PT

Blocker Displacement Amplification (BDA) is a rare allele enrichment technology with the potential to improve nucleic acid biomarker detection across broad oncology applications. Join NuProbe as we discuss BDA technology and highlight recent applications in oncology research. We will discuss research collaborations utilizing BDA next-generation sequencing panels to detect measurable residual disease in both NPM1+ acute myeloid leukemia (AML) and KMT2A-rearranged AML. We will also introduce a BDA qPCR research assay for detection of microsatellite instability without the need for a matched normal. For Research Use Only. Not for use in diagnostic procedures.

This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research; (AACR).


Nick Gallerani, Ph.D.
In his current role, Nicholas Gallerani, Ph.D., focuses on scientific communication and collaboration related to the applications and performance of NuProbe’s molecular technologies. Prior to joining NuProbe, he was a Fellow at Columbia Technology Ventures, where he assessed new technologies generated by Columbia University research labs. Nick received his Ph.D. in Pathobiology and Molecular Medicine from Columbia University and has co-authored four scientific publications.